CA3255735A1 - NEW TREATMENT FOR FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY (FSHD) - Google Patents
NEW TREATMENT FOR FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY (FSHD)Info
- Publication number
- CA3255735A1 CA3255735A1 CA3255735A CA3255735A CA3255735A1 CA 3255735 A1 CA3255735 A1 CA 3255735A1 CA 3255735 A CA3255735 A CA 3255735A CA 3255735 A CA3255735 A CA 3255735A CA 3255735 A1 CA3255735 A1 CA 3255735A1
- Authority
- CA
- Canada
- Prior art keywords
- myostatin
- antibody
- seq
- treatment
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22166261 | 2022-04-01 | ||
| EP22166261.2 | 2022-04-01 | ||
| PCT/EP2023/058218 WO2023187022A1 (en) | 2022-04-01 | 2023-03-30 | New treatment for facioscapulohumeral muscular dystrophy (fshd) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3255735A1 true CA3255735A1 (en) | 2023-10-05 |
Family
ID=81328333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3255735A Pending CA3255735A1 (en) | 2022-04-01 | 2023-03-30 | NEW TREATMENT FOR FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY (FSHD) |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250171526A1 (https=) |
| EP (1) | EP4504779A1 (https=) |
| JP (1) | JP2025511167A (https=) |
| KR (1) | KR20240165959A (https=) |
| CN (1) | CN119053619A (https=) |
| AU (1) | AU2023246859A1 (https=) |
| CA (1) | CA3255735A1 (https=) |
| IL (1) | IL315473A (https=) |
| MX (1) | MX2024011922A (https=) |
| TW (1) | TW202346345A (https=) |
| WO (1) | WO2023187022A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| AR107078A1 (es) | 2015-12-18 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso |
-
2023
- 2023-03-30 CA CA3255735A patent/CA3255735A1/en active Pending
- 2023-03-30 JP JP2024557991A patent/JP2025511167A/ja active Pending
- 2023-03-30 KR KR1020247032600A patent/KR20240165959A/ko active Pending
- 2023-03-30 AU AU2023246859A patent/AU2023246859A1/en active Pending
- 2023-03-30 WO PCT/EP2023/058218 patent/WO2023187022A1/en not_active Ceased
- 2023-03-30 IL IL315473A patent/IL315473A/en unknown
- 2023-03-30 TW TW112112383A patent/TW202346345A/zh unknown
- 2023-03-30 CN CN202380032060.9A patent/CN119053619A/zh active Pending
- 2023-03-30 EP EP23716257.3A patent/EP4504779A1/en active Pending
-
2024
- 2024-09-27 MX MX2024011922A patent/MX2024011922A/es unknown
- 2024-09-30 US US18/902,642 patent/US20250171526A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023246859A1 (en) | 2024-09-05 |
| TW202346345A (zh) | 2023-12-01 |
| AU2023246859A9 (en) | 2024-09-12 |
| EP4504779A1 (en) | 2025-02-12 |
| KR20240165959A (ko) | 2024-11-25 |
| JP2025511167A (ja) | 2025-04-15 |
| MX2024011922A (es) | 2024-11-08 |
| WO2023187022A1 (en) | 2023-10-05 |
| IL315473A (en) | 2024-11-01 |
| CN119053619A (zh) | 2024-11-29 |
| US20250171526A1 (en) | 2025-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020210134B2 (en) | Use of myostatin inhibitors and combination therapies | |
| US20240391989A1 (en) | Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies | |
| UA124269C2 (uk) | Застосування антагоністу il-13 для лікування атопічного дерматиту | |
| PT2625199T (pt) | Métodos de tratamento de psoríase usando antagonistas de il-17 | |
| US20220289831A1 (en) | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody | |
| US20240358704A1 (en) | Combined administration | |
| US20250011417A1 (en) | Methods for the treatment of thyroid eye disease | |
| CA3255735A1 (en) | NEW TREATMENT FOR FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY (FSHD) | |
| HK40112393A (zh) | 用於面肩肱型肌营养不良症(fshd)的新治疗 | |
| HK40103690A (zh) | 新颖的组合施用 | |
| EP4620483A1 (en) | Pharmaceutical composition comprising anti-rankl-ngf bispecific antibodies | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| WO2025106642A1 (en) | Methods for the treatment of thyroid eye disease | |
| WO2024129468A1 (en) | Methods for the treatment of noninfectious uveitis | |
| TW202511285A (zh) | 治療骨關節炎之方法 | |
| US20190247503A1 (en) | Methods for treating relapsing forms of multiple sclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240916 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250212 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250212 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250217 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20250217 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250218 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250221 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20250221 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250918 |